207 related articles for article (PubMed ID: 1601015)
1. Immunosuppressive treatment for juvenile myasthenia gravis.
Badurska B; Ryniewicz B; Strugalska H
Eur J Pediatr; 1992 Mar; 151(3):215-7. PubMed ID: 1601015
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and prognosis of myasthenia gravis in older people.
Evoli A; Batocchi AP; Minisci C; Di Schino C; Tonali P
J Am Geriatr Soc; 2000 Nov; 48(11):1442-8. PubMed ID: 11083321
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive drug therapy in myasthenia gravis.
Niakan E; Harati Y; Rolak LA
Arch Neurol; 1986 Feb; 43(2):155-6. PubMed ID: 3947257
[TBL] [Abstract][Full Text] [Related]
4. Response to plasmapheresis and immunosuppressive drug therapy in sixty myasthenia gravis patients.
Dau PC
Ann N Y Acad Sci; 1981; 377():700-8. PubMed ID: 6951494
[No Abstract] [Full Text] [Related]
5. Immunosuppressive drugs in treatment of myasthenia gravis.
Rowland LP
Ann N Y Acad Sci; 1971 Sep; 183():351-7. PubMed ID: 5287832
[No Abstract] [Full Text] [Related]
6. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis.
Bromberg MB; Wald JJ; Forshew DA; Feldman EL; Albers JW
J Neurol Sci; 1997 Sep; 150(1):59-62. PubMed ID: 9260858
[TBL] [Abstract][Full Text] [Related]
7. Immune regulation of experimental myasthenia.
Fuchs S; Bartfeld D; Eshhar Z; Feingold C; Mochly-Rosen D; Novick D; Schwartz M; Tarrab-Hazdai R
J Neurol Neurosurg Psychiatry; 1980 Jul; 43(7):634-43. PubMed ID: 7400824
[TBL] [Abstract][Full Text] [Related]
8. High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies.
Lin PT; Martin BA; Weinacker AB; So YT
Muscle Nerve; 2006 Mar; 33(3):433-5. PubMed ID: 16116645
[TBL] [Abstract][Full Text] [Related]
9. Plasma exchange combined with cytotoxic drugs and lymphocytapheresis for myasthenia gravis.
Valbonesi M; Garelli S; Zerbi D; Forlani G; Cornelio F; Pelucchetti D
Vox Sang; 1982; 43(3):142-6. PubMed ID: 7147857
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of myasthenia gravis by immunosuppressive non-steroidal drugs].
De Assis JL; Marchiori PE; Scaff M; Zambon AA
Arq Neuropsiquiatr; 1986 Jun; 44(2):109-16. PubMed ID: 3800686
[TBL] [Abstract][Full Text] [Related]
11. Ocular myasthenia gravis: response to long-term immunosuppressive treatment.
Sommer N; Sigg B; Melms A; Weller M; Schepelmann K; Herzau V; Dichgans J
J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):156-62. PubMed ID: 9048716
[TBL] [Abstract][Full Text] [Related]
12. Azathioprine as a single immunosuppressive drug in the treatment of myasthenia gravis.
Cosi V; Lombardi M; Erbetta A; Piccolo G
Acta Neurol (Napoli); 1993 Apr; 15(2):123-31. PubMed ID: 8328322
[TBL] [Abstract][Full Text] [Related]
13. Randomized Trial of Thymectomy in Myasthenia Gravis.
Wolfe GI; Kaminski HJ; Aban IB; Minisman G; Kuo HC; Marx A; Ströbel P; Mazia C; Oger J; Cea JG; Heckmann JM; Evoli A; Nix W; Ciafaloni E; Antonini G; Witoonpanich R; King JO; Beydoun SR; Chalk CH; Barboi AC; Amato AA; Shaibani AI; Katirji B; Lecky BR; Buckley C; Vincent A; Dias-Tosta E; Yoshikawa H; Waddington-Cruz M; Pulley MT; Rivner MH; Kostera-Pruszczyk A; Pascuzzi RM; Jackson CE; Garcia Ramos GS; Verschuuren JJ; Massey JM; Kissel JT; Werneck LC; Benatar M; Barohn RJ; Tandan R; Mozaffar T; Conwit R; Odenkirchen J; Sonett JR; Jaretzki A; Newsom-Davis J; Cutter GR;
N Engl J Med; 2016 Aug; 375(6):511-22. PubMed ID: 27509100
[TBL] [Abstract][Full Text] [Related]
14. The favourable effect of cyclophosphamide in myasthenia gravis.
Nouza K; Smat V
Rev Fr Etud Clin Biol; 1968 Feb; 13(2):161-3. PubMed ID: 5654288
[No Abstract] [Full Text] [Related]
15. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
[TBL] [Abstract][Full Text] [Related]
16. Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment.
Fattorossi A; Battaglia A; Buzzonetti A; Ciaraffa F; Scambia G; Evoli A
Immunology; 2005 Sep; 116(1):134-41. PubMed ID: 16108825
[TBL] [Abstract][Full Text] [Related]
17. Maintenance immunosuppression in myasthenia gravis.
Gotterer L; Li Y
J Neurol Sci; 2016 Oct; 369():294-302. PubMed ID: 27653912
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of myasthenia gravis with plasmapheresis (author's transl)].
Reuther P; Wiebecke D; Hertel G; Böske A; Mertens HG
Dtsch Med Wochenschr; 1979 Dec; 104(51):1806-10. PubMed ID: 520174
[TBL] [Abstract][Full Text] [Related]
19. Myasthenia gravis in children: a longitudinal study.
Ashraf VV; Taly AB; Veerendrakumar M; Rao S
Acta Neurol Scand; 2006 Aug; 114(2):119-23. PubMed ID: 16867035
[TBL] [Abstract][Full Text] [Related]
20. Maintenance immunosuppression in myasthenia gravis, an update.
Morren J; Li Y
J Neurol Sci; 2020 Mar; 410():116648. PubMed ID: 31901719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
